Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 03 - 23 tags : Phase 3 save search
Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2
Published: 2021-03-23 (Crawled : 18:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.5%
H: 0.31%
C: -1.28%
phase 1 antiviral phase 3 phase 2 sars-cov-2
Alnylam to Present Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the American Academy of Neurology Virtual Annual Meeting 2021
Published: 2021-03-23 (Crawled : 14:00) - biospace.com/
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.53%
H: 0.18%
C: -3.29%
results phase 3
Citius Pharmaceuticals to Highlight its Phase 3 Clinical Trial Product Mino-Lok® at Benzinga Biotech Small Cap Conference on March 25
Published: 2021-03-23 (Crawled : 14:00) - biospace.com/
CTXR | $0.8 -1.99% -2.02% 6.3M
|
Health Technology
|
| O: -1.51%
H: 4.08%
C: 1.53%
biotech phase 3 iot trial conference
Oramed Initiates Second Phase 3 Oral Insulin Study Under the FDA's Approved Dual Concurrent Protocol
Published: 2021-03-23 (Crawled : 13:00) - prnewswire.com
ORMP | $2.19 -6.01% -6.39% 240K
|
Health Technology
|
| O: 17.92%
H: 4.0%
C: -10.7%
fda insulin phase 3 approval fda approval
IDEAYA Announces Dose Expansion in Phase 1/2 Study of IDE196 and Binimetinib Combination in Metastatic Uveal Melanoma Based on Early Clinical Activity
Published: 2021-03-23 (Crawled : 11:00) - biospace.com/
IDYA | $37.63 -6.32% -6.75% 820K
|
Health Technology
|
| O: -1.76%
H: 3.68%
C: 0.18%
phase 1 expansion phase 3 phase 2
Phase 3 Trial Shows REGEN-COV™ (casirivimab with imdevimab) Antibody Cocktail Reduced Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients
Published: 2021-03-23 (Crawled : 07:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.2%
H: 0.22%
C: -1.32%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.61%
H: 0.53%
C: -3.37%
covid antibody phase 3 trial casirivimab
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.